Evidence map›Paper›PMID 27591036›Full record

ArticleBMJ case reports2016

Orolingual angioedema to alteplase. Identify, counsel and monitor at risk patients.

Christopher Timmis, Elliot Epstein, Mohmad Salim

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Christopher TimmisDepartment of Anaesthetics, Walsall Manor Hospital, Walsall, UK.
Elliot EpsteinDepartment of Medicine, Walsall Manor Hospital, Walsall, UK.
Mohmad SalimDepartment of Anaesthetics, Walsall Manor Hospital, Walsall, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Orolingual angioedema (OLA) is a known complication of intravenous alteplase used to treat ischaemic stroke. The incidence may be as high as 5.1%. ACE inhibitors are thought to increase the risk of developing this potentially life-threatening complication. This case report demonstrates how we may improve in the identification of risk factors in the history; the counselling of patients appropriately; in seeking alternative therapies such as mechanical thrombectomy; and in the monitoring of patients for signs of OLA once alteplase has been given.

Indexed as

AgedAngioedemaFemaleFibrinolytic AgentsHumansMouth DiseasesRisk FactorsStrokeTissue Plasminogen ActivatorFibrinolytic AgentsTissue Plasminogen Activator

Identifiers

PMID27591036
PMCPMC5020716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.